Vertex Pharmaceuticals Incorporated
VRTXNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $136.58B
- P/E (TTM)
- 31.00
- Forward P/E
- 25.71
- Dividend yield
- -
- 52-week range
- $403.16$560.25
- Volume (live)
- -
- Avg. volume (3M)
- 1.18M
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price & Financial Analysis
Vertex Pharmaceuticals Incorporated Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $521.30 - $537.81 |
|---|---|
| 52-Week High | $560.25 |
| 52-Week Low | $403.16 |
| Open | $527.18 |
| Volume (last close) | 1.64M |
| Average Volume (3M) | 1.18M |
| Revenue (TTM) | 12.59B |
|---|---|
| Net Income (TTM) | 4.41B |
| Free Cash Flow (TTM) | 3.80B |
| EPS (TTM) | $17.19 |
| Profit Margin | 35.00% |
| Operating Margin | 37.94% |
| Return on Equity (ROE) | 21.76% |
| Debt to Equity | 0.10 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Market Cap | 136.58B |
|---|---|
| Shares Outstanding | 255.20M |
| P/E Ratio (TTM) | 31.00 |
| Forward P/E | 25.71 |
| Price to Sales (P/S) | 10.85 |
| Price to Book (P/B) | 6.75 |
| EV/EBITDA | 25.14 |
| 50-Day MA | $522.47 |
|---|---|
| 200-Day MA | $476.46 |
| 1-Year Change | +26.63% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Vertex Pharmaceuticals Incorporated at a Glance
As of the Oct 22, 2026 close, Vertex Pharmaceuticals Incorporated (VRTX) has a market capitalization of $136.58B. The stock trades at 31.0× trailing earnings, 25.7× forward earnings and 10.8× sales. Over the trailing twelve months it earned $4.41B on revenue of $12.59B (a 35.0% profit margin) and generated $3.80B of free cash flow. Revenue grew 10.6% year over year.
As of its latest reported balance sheet, it holds $6.14B in cash and securities against $1.98B of debt, a net cash position of $4.17B.
Vertex Pharmaceuticals Incorporated does not currently pay a dividend.
The share price is up 26.6% over the past year. At $535.17 (the Oct 22, 2026 close) it sits within its 52-week range of $403.16 to $560.25, above its 200-day moving average of $476.46.
Based on 27 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $589.45, 10.1% above the Oct 22, 2026 close.
Frequently Asked Questions About Vertex Pharmaceuticals Incorporated
What is the current stock price for VRTX?
As of the Oct 22, 2026 close, VRTX stock trades at $535.17. The 52-week range is $403.16–$560.25, with a day range of $521.30–$537.81.
What is the P/E ratio for VRTX?
As of the Oct 22, 2026 close, Vertex Pharmaceuticals Incorporated's trailing twelve-month (TTM) P/E ratio is 31.0, meaning investors pay $31.0 for every $1 of annual earnings. The forward P/E is 25.7, reflecting analyst expectations for future earnings. Vertex Pharmaceuticals Incorporated operates in the Healthcare sector.
Does VRTX pay dividends?
Vertex Pharmaceuticals Incorporated does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for VRTX?
Based on ratings from 27 professional analysts over the last 90 days, the consensus for VRTX is Buy. The average 12-month price target is $589.45, a 10.1% upside from the Oct 22, 2026 close of $535.17.
What is the market cap of VRTX?
As of the Oct 22, 2026 close, Vertex Pharmaceuticals Incorporated's market capitalization is $136.58B, classifying it as a large-cap company. Vertex Pharmaceuticals Incorporated operates in the Healthcare sector within the Biotechnology industry.